Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Status:
Active, not recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This phase II trial evaluates how effective 560 mg of ibrutinib taken by mouth daily is in
the treatment of classical Hodgkin lymphoma which recurs or does not respond to initial
treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth, by altering the environment around the tumor or by affecting the
immune system.